Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?

Simply Wall St.07-02

AdvertisementWhy this FDA milestone matters for Mesoblast Mesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648957086?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-02 13:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648957086","market":"hk","top_or_hot":-1,"title":"Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy this FDA milestone matters for Mesoblast Mesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-02 13:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy this FDA milestone matters for Mesoblast Mesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r","article_id":"2648957086","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648957086","pubTimestamp":1782970812,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why this FDA milestone matters for Mesoblast\nMesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and accepted a modular review request for patients with LVAD-related risks.\nThis regulatory step, supported by existing Orphan Drug and Regenerative Medicine Advanced Therapy designations, provides formal structure around the approval process for Mesoblast’s late-stage heart failure program and clarifies the path for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4097":"系统软件","MSB.AU":"MESOBLAST LTD","BK4006":"钢铁","MSB":"美莎比信托","BK7067":"生物科技","PRGS":"Progress Software Corporation","BK7508":"医药生物股","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK7501":"新冠治疗股","LABU":"三倍做多标普生物-Direxion","BK4588":"碎股"},"translate_title":"FDA对Rexlemestrocel L取得进展后，Mesoblast(ASX：MSB)的价值是否被低估？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1.5,"LABU":1.5,"MSB":1.5,"MSB.AU":1.5},"content_text":"AdvertisementWhy this FDA milestone matters for Mesoblast Mesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and accepted a modular review request for patients with LVAD-related risks. This regulatory step, supported by existing Orphan Drug and Regenerative Medicine Advanced Therapy designations, provides formal structure around the approval process for Mesoblast’s late-stage heart failure program and clarifies the path for future FDA interactions. See our latest analysis for Mesoblast. The FDA progress appears to have shifted sentiment in recent sessions, with Mesoblast’s A$2.04 share price posting a 1-day share price return of 4.35% after a weaker year to date. A 3-year total shareholder return of 87.91% points to strong longer term gains despite interim volatility. If you are watching how regulatory milestones can change the outlook for high risk, high reward biotech ideas, it could be a good moment to scan for 9 healthcare AI stocks With Mesoblast shares still down 26.35% year to date despite an 87.91% 3 year total return and trading below the average analyst price target, the key question is whether this FDA progress is underappreciated or already fully priced in. Most Popular Narrative: 46.7% Undervalued Mesoblast's most followed narrative places fair value at A$3.83 per share compared with the recent A$2.04 close, which frames the current FDA milestone against a much broader growth story.  The chronic low back pain Phase III program for rexlemestrocel L targets millions of patients and a setting where opioid use is common, aligning the product with an ongoing healthcare shift toward non opioid therapies. If the program succeeds, it could contribute substantially to diversified revenue and reduce reliance on a single product.  Read the complete narrative. Want to see what kind of revenue ramp and margin profile sits behind that A$3.83 figure? The narrative leans on rapid top line expansion, a sharp swing into profitability and a future earnings multiple that assumes investors will pay up for those outcomes. Result: Fair Value of A$3.83 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the Mesoblast story could shift quickly if key trials disappoint or if Ryoncil uptake and reimbursement support do not build as analysts expect. Find out about the key risks to this Mesoblast narrative. Another view on Mesoblast valuation The DCF style narrative points to Mesoblast being undervalued, yet the current pricing tells a different story. At A$2.04, the stock trades on a P/S of 27.9x compared with 15.6x for the Australian biotech industry and a fair ratio of 4.2x, which implies substantial valuation risk if expectations reset. That kind of gap invites a simple question: are you comfortable paying a much higher revenue multiple today in return for the growth scenario implied by analysts, or would you rather wait for either fundamentals or the price to shift closer to that fair ratio before acting? See what the numbers say about this price — find out in our valuation breakdown. ASX:MSB P/S Ratio as at Jul 2026Next Steps If this mix of optimism and caution around Mesoblast resonates, do not wait. Check the data for yourself and weigh both sides using the 3 key rewards. Looking for more ideas beyond Mesoblast? If Mesoblast has your attention, do not stop here. Broader context across sectors and risk profiles can inform your decisions and keep your watchlist up to date.  Scan screener containing 12 high quality undiscovered gems for companies that combine solid fundamentals with limited market attention. Review 9 resilient stocks with low risk scores to explore stocks built around resilience and lower historical risk scores. Consider 6 dividend fortresses for stocks focused on higher yields and income characteristics.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648957086","isCrawlerRequest":true}